Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial

BACKGROUND: The Strategic Timing of AntiRetroviral Treatment (START) trial demonstrated that immediate (at CD4+ >500 cells/µL) vs deferred (to CD4+ <350 cells/µL or AIDS) antiretroviral therapy (ART) initiation reduced risk for AIDS and serious non-AIDS (SNA). We investigated associations of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Jason V, Sharma, Shweta, Grund, Birgit, Rupert, Adam, Metcalf, Julia A, Schechter, Mauro, Munderi, Paula, Aho, Inka, Emery, Sean, Babiker, Abdel, Phillips, Andrew, Lundgren, Jens D, Neaton, James D, Lane, H Clifford
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751061/
https://www.ncbi.nlm.nih.gov/pubmed/29308409
http://dx.doi.org/10.1093/ofid/ofx262

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751061/
https://www.ncbi.nlm.nih.gov/pubmed/29308409
http://dx.doi.org/10.1093/ofid/ofx262

Ejemplares similares